March 13, 2020 / 11:45 AM / 15 days ago

BRIEF-GW Pharma Submits Type II Variation Application To The European Medicines Agency To Expand The Use Of Epidyolex

March 13 (Reuters) - GW Pharmaceuticals PLC:

* GW PHARMACEUTICALS SUBMITS TYPE II VARIATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY (EMA) TO EXPAND THE USE OF EPIDYOLEX®, (CANNABIDIOL) ORAL SOLUTION, FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (TSC) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below